Drug Insights

Is Tirbanibulin approved by the FDA?

9 July 2024
3 min read

Tirbanibulin, marketed under the brand name Klisyri, is a topical ointment used primarily to treat actinic keratosis, a skin condition caused by repeated exposure to ultraviolet light from the sun or indoor tanning. Tirbanibulin was approved by the US Food and Drug Administration (FDA) on December 14, 2020, for the treatment of actinic keratosis on the face or scalp.

Uses and Administration

Uses:

  • Tirbanibulin is indicated for the treatment of actinic keratosis on the face or scalp.
  • It is not suitable for other skin conditions or purposes not listed in the medication guide.

Administration:

  • The ointment should be applied once daily for five consecutive days.
  • Apply only enough medication to cover the affected area.
  • Wash hands with soap and water after application.
  • Avoid covering the treated skin area with a bandage.
  • Do not wash or touch the treated area for at least 8 hours after application.
  • Each single-dose packet is intended for one use only; discard the packet after use.

Side Effects

Common Side Effects:

  • Itching or pain at the application site

Serious Side Effects:

  • Redness, swelling, flaking, scaling, peeling, or crusting of treated skin
  • Blisters, pus, ulcers, or breakdown of the skin

If any severe side effects occur, contact your doctor immediately. You can report side effects to the FDA at 1-800-FDA-1088.

Warnings and Precautions

  • Follow all directions on your prescription label and medication guides.
  • Inform your healthcare providers about all your medical conditions, allergies, and treatments.
  • Delay starting tirbanibulin if you have other skin treatments until your skin has healed.
  • Not approved for use by individuals under 18 years old.
  • If you are pregnant or breastfeeding, consult your doctor before using tirbanibulin.

Drug Interactions

Topical medications like tirbanibulin are unlikely to interact with other drugs you use. However, it is essential to inform your healthcare providers about all the medications you are taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal products.

Conclusion

This medication offers a targeted treatment option for patients with this condition. As with all medications, it is crucial to follow the prescribed instructions and consult your healthcare provider with any concerns or questions regarding its use.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Johnson & Johnson Wins FDA and European Commission Nod for SIRTURO® (bedaquiline)
Latest Hotspot
4 min read
Johnson & Johnson Wins FDA and European Commission Nod for SIRTURO® (bedaquiline)
9 July 2024
Johnson & Johnson revealed that the U.S. Food and Drug Administration has granted conventional approval for SIRTURO (bedaquiline).
Read →
Is Berotralstat approved by the FDA?
Drug Insights
3 min read
Is Berotralstat approved by the FDA?
9 July 2024
Berotralstat received approval from the US Food and Drug Administration (FDA) on December 3, 2020.
Read →
Sobi Files FDA Application for SEL-212, a Chronic Refractory Gout Treatment
Latest Hotspot
3 min read
Sobi Files FDA Application for SEL-212, a Chronic Refractory Gout Treatment
9 July 2024
Sobi submits biologics license application to the FDA for SEL-212, targeting chronic refractory gout treatment.
Read →
Is Setmelanotide approved by the FDA?
Drug Insights
3 min read
Is Setmelanotide approved by the FDA?
9 July 2024
Setmelanotide received FDA approval on November 25, 2020. The approval was granted for the treatment of obesity caused by rare genetic disorders.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.